NEOG - ネオゲン （Neogen Corporation）

LANSING, Mich., May 30, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 43rd Annual William Blair Growth Stock Conference in Chicago, Illinois, on Tuesday, June 6, 2023. John Adent, Neogen''s President and Chief Executive…

https://www.investing.com/news/assorted/neogen-corp-launches-new-assays-for-natural-toxin-detection-432SI-3077237

New Reveal Q+ EndPoint assays designed for use in high-output situations LANSING, Mich., May 9, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that it has launched two new assays for the detection of natural toxins, Reveal Q+ for DON EndPoint and Reveal Q+ for…

WASHINGTON, April 17, 2023 (GLOBE NEWSWIRE) -- The Global Allergy Diagnostics Market is valued at USD 5327.20 Million in 2022 and is projected to reach a value of USD 11841.27 Million by 2030 at a CAGR (Compound Annual Growth Rate) of 10.50% over the forecast period 2023-2030. Market Overview Allergy diagnostics are medical tests used to diagnose and identify allergies. They are used to determine what is causing an allergic reaction and to determine the allergies a person is suffering from. Allergy diagnostics tests measure the number of specific antibodies or proteins in the body that are associated with allergies. Common allergy diagnostics test includes skin prick tests, blood tests, and patch tests. Recent advances in technology have enabled the development of rapid, easy-to-use, and accurate allergy diagnostics tests. This has resulted in an increased demand for allergy diagnostics tests in both developed and developing countries. The Global Allergy Diagnostics Market is projected to continue to grow at a steady rate due to the increasing prevalence of allergies, rising healthcare expenditure, and the availability of innovative diagnostic techniques.

NEWARK, DE / ACCESSWIRE / April 14, 2023 / The global Veterinary Molecular Diagnostics Market is anticipated to be worth US$ 194.47 million in 2023, exceeding US$ 377.22 million by 2033. Between 2023 and 2033, the demand for veterinary molecular diagnostics is anticipated to expand at a CAGR of 6.84% . The veterinary molecular diagnostics industry is being driven by the increasing demand for animal-derived food products and the growing incidence of animal diseases. The increasing adoption of companion animals and their increasing healthcare expenditure is also contributing to the growth of the industry. In addition, the development of advanced technologies and the increasing use of molecular diagnostic tests for animal disease diagnosis is boosting the growth of the veterinary molecular diagnostics industry. The high cost of molecular diagnostics tests, the lack of skilled professionals, and the stringent regulatory framework are some of the major challenges faced by the veterinary molecular diagnostics industry.

LEXINGTON, Ky., March 1, 2022 /PRNewswire/ -- NEOGEN Corporation (NASDAQ: NEOG) announced today that it has added a ready-to-use formulation of their Synergize® disinfectant to their biosecurity portfolio. Synergize RTU is a new formulation of the company''s Synergize disinfectant that has…

Neogen <> said it has added a new chemiluminescent substrate as part of the K-Blue product line.The company said K-Blue Luminescent is a two-component, luminol-based substrate…

Neogen Corp. (NEOG) shares closed today at 1.8% above its 52 week low of $38.24, giving the company a market cap of $4B. The stock is currently down 14.3% year-to-date, down 6.8% over the past 12 months, and up 56.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 21.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 39.1% The company's stock price performance over the past 12 months lags the peer average by -570.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 303.8% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Company is merging operations with 3M unit in deal long considered by Neogen, CEO tells Cramer.

Neogen <> said it has added a new chemiluminescent substrate as part of the K-Blue product line.The company said K-Blue Luminescent is a two-component, luminol-based substrate…

Neogen Corp. (NEOG) shares closed today at 1.8% above its 52 week low of $38.24, giving the company a market cap of $4B. The stock is currently down 14.3% year-to-date, down 6.8% over the past 12 months, and up 56.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.9%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 21.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 39.1% The company's stock price performance over the past 12 months lags the peer average by -570.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 303.8% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Company is merging operations with 3M unit in deal long considered by Neogen, CEO tells Cramer.

Neogen Corporation (NASDAQ:NEOG) stock rose 0.43% (As on Dec 22, 11:24:41 AM UTC-4, Source: Google Finance) though the company in the second quarter of FY The post Neogen Corporation (NASDAQ:NEOG) earnings falls appeared first on FXDailyReport.Com .

Neogen (NASDAQ:NEOG) announced its quarterly earnings results on Tuesday. The company reported $0.10 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.07), MarketWatch Earnings reports. Neogen had a net margin of 12.74% and a return on equity of 7.57%. The firm had revenue of $130.50 million during the quarter, []